Gitnux/Report 2026

Pediatric Brain Tumor Statistics

With a 5 year relative survival rate of 75% for children with brain and other CNS tumors in the United States, Pediatric Brain Tumor outcomes can look steady until you zoom in on glioblastoma where survival drops to about 22%, and medulloblastoma where median diagnosis is 6 years and therapies are rapidly shifting. This page connects the survival contrasts to today’s most actionable clinical imaging and treatment advances, from MRI guided diagnosis to emerging targeted, radiation planning, and AI supported radiotherapy workflows.
25Statistics
14Sources
6Sections
1Visuals
6mRead
June 29, 2026Updated
Pediatric Brain Tumor Statistics
Marcus AfolabiWritten by Marcus Afolabi·Edited by Nicholas Chambers·Fact-checked by Nikolas Papadopoulos
Published ·Updated
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 43 days
The 5-year relative survival rate for children with brain and other CNS tumors in the United States reaches 75%. Median age at diagnosis for pediatric medulloblastoma stands at 6 years, while the rate falls to about 22% for children with glioblastoma. This article compiles incidence figures, treatment outcomes, diagnostic approaches, and trial trends across these tumor types.

Key Takeaways

  • The 5-year relative survival rate for children with brain and other CNS tumors in the United States is 75%
  • The median age at diagnosis of pediatric medulloblastoma is 6 years
  • About 20% of pediatric ependymomas arise in the fourth ventricle
  • The global pediatric oncology therapeutics market was forecast to grow at a CAGR of 11.5% from 2024 to 2032
  • The global medulloblastoma therapeutics market is forecast to grow at a CAGR of 12.2% from 2024 to 2032
  • The global glioma therapeutics market is forecast to grow at a CAGR of 10.7% from 2024 to 2032
  • The 5-year relative survival for children with glioblastoma is about 22%
  • High-dose chemotherapy with autologous stem cell rescue is used in about 20% of recurrent pediatric medulloblastoma cases
  • In a phase 2 trial of vismodegib for adults with basal cell-related tumors, hedgehog pathway inhibition showed an objective response rate of 19% (benchmark for pathway-targeted therapy relevance to SHH-driven tumors)
  • MRI is the primary diagnostic imaging modality for pediatric brain tumors
  • Neurofibromatosis type 2 (NF2) is associated with meningioma and ependymoma syndromes; germline NF2 mutations account for a subset of ependymoma cases
  • A review reports that 18F-FET PET can change management in suspected recurrent glioma cases in a clinically meaningful fraction of patients
  • Academic and nonprofit consortia increasingly combine genomic profiling with clinical trial matching (basket/umbrella designs) for pediatric brain tumor patients
  • Molecularly targeted therapies are being trialed across multiple pediatric brain tumor subgroups; targeted trials represent a growing share of pediatric neuro-oncology studies in registries
  • The International Cancer Genome Consortium (ICGC) established a Pediatric Cancer program in 2016 with the goal to sequence 2,000 pediatric cancer genomes

Pediatric brain tumor survival is improving, with MRI-led diagnosis and targeted therapies driving better outcomes.

Related reading

01 · Category

Incidence & Demographics3 stats

01
The 5-year relative survival rate for children with brain and other CNS tumors in the United States is 75%[1]
02
The median age at diagnosis of pediatric medulloblastoma is 6 years[2]
03
About 20% of pediatric ependymomas arise in the fourth ventricle[3]
Interpretation

Incidence & Demographics Interpretation

Within pediatric brain tumor incidence and demographics, the median age for medulloblastoma is 6 years while roughly 20% of ependymomas originate in the fourth ventricle, and despite these age and tumor-location patterns the 5 year relative survival rate in the United States is 75%.

02 · Category

Market Size5 stats

01
The global pediatric oncology therapeutics market was forecast to grow at a CAGR of 11.5% from 2024 to 2032[4]
02
The global medulloblastoma therapeutics market is forecast to grow at a CAGR of 12.2% from 2024 to 2032[4]
03
The global glioma therapeutics market is forecast to grow at a CAGR of 10.7% from 2024 to 2032[4]
04
The CAR-T therapy market is forecast to reach US$40.2 billion by 2032[5]
05
The radiation therapy equipment market is forecast to reach US$14.7 billion by 2032[6]
Interpretation

Market Size Interpretation

The pediatric brain tumor market is set for strong growth, with pediatric oncology therapeutics projected to expand at an 11.5% CAGR from 2024 to 2032 and related segments like medulloblastoma therapeutics rising at a 12.2% CAGR, signaling expanding investment in treatment options across this market category.

03 · Category

Treatment & Outcomes7 stats

01
The 5-year relative survival for children with glioblastoma is about 22%[1]
02
High-dose chemotherapy with autologous stem cell rescue is used in about 20% of recurrent pediatric medulloblastoma cases[3]
03
In a phase 2 trial of vismodegib for adults with basal cell-related tumors, hedgehog pathway inhibition showed an objective response rate of 19% (benchmark for pathway-targeted therapy relevance to SHH-driven tumors)[7]
04
In the randomized trial of systemic therapy for children with high-risk medulloblastoma, 3-year progression-free survival was 59% (standard vs investigational comparisons reported in the trial)[8]
05
In the randomized phase 3 trial for newly diagnosed pediatric high-risk medulloblastoma, overall survival at 5 years was 77% for the standard arm[9]
06
In the St. Jude Total Therapy study for pediatric medulloblastoma, 5-year event-free survival exceeded 75% (risk-adapted protocols)[10]
07
Leptomeningeal dissemination occurs in approximately 30%–40% of children at diagnosis for certain embryonal tumors involving CNS spread[3]
Interpretation

Treatment & Outcomes Interpretation

For Pediatric Brain Tumor treatment and outcomes, the best signals come from medulloblastoma where modern risk adapted and randomized strategies reach 5-year overall survival around 77% and 5-year event free survival above 75%, even as glioblastoma outcomes remain far lower with only about 22% 5-year relative survival.

More related reading

04 · Category

Diagnostics & Biomarkers2 stats

01
MRI is the primary diagnostic imaging modality for pediatric brain tumors[11]
02
Neurofibromatosis type 2 (NF2) is associated with meningioma and ependymoma syndromes; germline NF2 mutations account for a subset of ependymoma cases[3]
Interpretation

Diagnostics & Biomarkers Interpretation

MRI is the primary diagnostic imaging tool for pediatric brain tumors, and when paired with biomarker-oriented genetics like germline NF2 mutations linked to ependymoma syndromes, it suggests diagnostics increasingly combine imaging-first detection with targeted molecular risk context.

06 · Category

Regulatory & Policy3 stats

01
The International Cancer Genome Consortium (ICGC) established a Pediatric Cancer program in 2016 with the goal to sequence 2,000 pediatric cancer genomes[13]
02
The Cancer Moonshot initiative set a target to reduce cancer death rates by at least 50% by 2047 (policy-level public health target)[11]
03
The US FDA Modernization Act 2.0 (2022) included provisions affecting pediatric oncology development through expanded data standards and review modernization[14]
Interpretation

Regulatory & Policy Interpretation

Regulatory and policy efforts are increasingly pushing pediatric brain tumor research forward through concrete targets and standards, from the ICGC’s 2016 goal to sequence 2,000 pediatric cancers to the Cancer Moonshot’s aim to cut cancer deaths by at least 50 percent by 2047 and the FDA Modernization Act 2.0’s 2022 updates expanding data requirements for pediatric oncology.
report visual · Comparison

Survival varies widely by pediatric brain tumor type

5-year relative survival rates differ substantially between broader brain/CNS tumors and glioblastoma.

The 5-year relative survival rate for children with brain and other CNS tumors in the United States is 75%75%
The 5-year relative survival for children with glioblastoma is about 22%
22%
The median age at diagnosis of pediatric medulloblastoma is 6 years
6
source-verifiedseer.cancer.gov · acsjournals.onlinelibrary.wiley.com
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Marcus Afolabi. (2026, February 13). Pediatric Brain Tumor Statistics. Gitnux. https://gitnux.org/pediatric-brain-tumor-statistics
MLA
Marcus Afolabi. "Pediatric Brain Tumor Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pediatric-brain-tumor-statistics.
Chicago
Marcus Afolabi. 2026. "Pediatric Brain Tumor Statistics." Gitnux. https://gitnux.org/pediatric-brain-tumor-statistics.

Sources & references

14 sources cited across this report

  1. seer.cancer.gov
  2. acsjournals.onlinelibrary.wiley.com
  3. ncbi.nlm.nih.gov
  4. imarcgroup.com
  5. fortunebusinessinsights.com
  6. alliedmarketresearch.com
  7. nejm.org
  8. ascopubs.org
  9. thelancet.com
  10. cancergenome.nih.gov
  11. cancer.gov
  12. clinicaltrials.gov
  13. icgc.org
  14. congress.gov